<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505648</url>
  </required_header>
  <id_info>
    <org_study_id>2004/077/HP</org_study_id>
    <nct_id>NCT00505648</nct_id>
  </id_info>
  <brief_title>Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)</brief_title>
  <acronym>DRESS2</acronym>
  <official_title>Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and tolerance of Tegeline® treatment in hypersensitivity syndrome. Immunological
      study of the T cell index phenotype and functionality in hypersensitivity syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Side effects valuation
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>express healing of visceral attacks, healing of polyadenopathy and body temperature, biological abnormal values normalisation, express healing of cutaneous and mucous diseases immunological study of the T cell index phenotype</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Drug Hypersensitivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegeline®</intervention_name>
    <description>2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18

          -  Cutaneous and/or mucous eruption

          -  Polyadenopathy

          -  Body temperature &gt; 38°C

          -  Hematology disorders : Hypereosinophily &gt; 1.5 G/l, lymphocytosis &gt; 5G/l, atypical
             blood lymphocytes

          -  Consent obtained from patient

        Exclusion Criteria:

          -  Age &lt; 18

          -  No consent obtained from patient

          -  IgV allergy

          -  Dress with very sérious visceral attack and vital diagnostic (sharp cardiac
             insufficiency, sharp respiratory insufficiency, hepatic insufficiency, sharp renal
             insufficiency)

          -  Oral therapy or immunosuppressive therapy (Methotrexate, cyclosporine,
             cyclophosphamide, etc.)

          -  IgA deficiency,

          -  MCI &gt;=35

          -  Sharp renal insufficiency before Dress with creatinaemia &lt; 60 ml/min (Cockroft)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal JOLY, MD-PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Dermatologique - Hôpital Charles Nicolle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH-rouen</name>
      <address>
        <city>Rouen</city>
        <state>Seine maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JOLY</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypersensitivity</keyword>
  <keyword>Syndrome</keyword>
  <keyword>Tegeline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

